Westpark Capital Begins Coverage on Aligos Therapeutics (NASDAQ:ALGS)

Stock analysts at Westpark Capital began coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a report released on Thursday,Benzinga reports. The firm set a “buy” rating and a $48.00 price target on the stock.

ALGS has been the subject of a number of other research reports. UBS Group began coverage on Aligos Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Wednesday, January 21st. Wall Street Zen cut shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Jefferies Financial Group started coverage on Aligos Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $48.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Aligos Therapeutics has an average rating of “Moderate Buy” and an average price target of $41.50.

Aligos Therapeutics Trading Down 5.4%

Aligos Therapeutics stock opened at $6.66 on Thursday. Aligos Therapeutics has a 12-month low of $3.76 and a 12-month high of $13.69. The stock has a market cap of $41.23 million, a P/E ratio of -0.78 and a beta of 2.67. The company has a fifty day simple moving average of $7.30 and a 200-day simple moving average of $8.72.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.09) by $0.18. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%.The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.27 million. As a group, sell-side analysts forecast that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Institutional Trading of Aligos Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. increased its position in Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after buying an additional 9,000 shares during the period. NorthCrest Asset Manangement LLC bought a new position in shares of Aligos Therapeutics in the third quarter valued at about $98,000. Susquehanna International Group LLP acquired a new position in Aligos Therapeutics during the 3rd quarter worth about $99,000. XTX Topco Ltd bought a new stake in Aligos Therapeutics during the 2nd quarter worth about $100,000. Finally, HRT Financial LP acquired a new position in Aligos Therapeutics during the 4th quarter worth $106,000. 60.43% of the stock is owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.